Kairos Pharma, Ltd. (KAPA)

US · Healthcare · Biotechnology

$1.810.00%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-1.4M

EPS

$-0.06

EPS estimate

$-0.09

EPS came in at -0.06 against a street estimate of -0.09 — a beat of 33.3%.

Market cap

$6.3M

Forward P/E

0.0

P/B

1.49

Book value

$1.37

EPS (TTM)

$-1.97

52-week high

$10.29

52-week low

$1.51

50-day MA

$2.14

200-day MA

$3.81

Analysts rate Kairos Pharma, Ltd. a buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $49.00.

Insiders

33.61%

Institutions

7.82%

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Kairos Pharma, Ltd. — free to start.

Data updated 2026-09-18.